The UK Mounjaro Market: Who Sells It, How Prices Are Set and How It Has Changed

Three ways to get Mounjaro in the UK

• NHS. Tirzepatide is approved for weight management by NICE but is being introduced in phases, starting with people at the highest BMI who also have several weight-related conditions. Waits are long in most areas. Our NHS guide covers eligibility.
• Private pharmacy. The route almost everyone uses: a GPhC-registered online pharmacy, an online consultation, a prescriber decision and a tracked cold-chain delivery. This is the market this page describes.
• The illegal market. Counterfeit and unlicensed pens sold through social media and copycat sites. The MHRA has warned about these repeatedly and seized falsified 15mg pens in the UK. Our fake pen guide covers how to check yours.

How the private market is structured

Every legal pen follows the same chain: Eli Lilly, then a wholesaler, then a registered pharmacy, then a courier to you. That means pharmacies buy broadly the same product at broadly the same cost. Competition therefore happens entirely in the layer the pharmacy adds on top.

Three kinds of seller dominate:

• Large online doctor brands, often owned by high-street or telehealth groups. Heavy marketing, polished consultations, and prices that usually sit mid-table or above. They rely on brand recognition rather than price.
• Mid-size specialists that focus on weight management. Competitive prices, frequent discount codes, subscription plans.
• Smaller independents. Often the cheapest at a given dose, usually with the fastest human support, and the group most likely to price match. They are also the group large competitors most often exclude from their own price-match lists.

The practical consequence for a patient is that brand recognition is a poor guide to price. In our daily tracking, the cheapest total at a given dose is more often a name you have not heard of than one advertised on television.

How a private price is actually built

An advertised Mounjaro price is rarely the amount that leaves your account. The total is:

• The pen. The pharmacy's cost plus margin. This is most of the price and the part that moved in September 2025.
• The consultation. Bundled by most, charged separately by some.
• Delivery. Free to around £8, occasionally more for named-day or Saturday services.
• Discounts. Usually first-order only, occasionally applying to repeats, sometimes tied to a subscription you must remember to cancel.

This is why Monj ranks by the total including delivery with any working code applied, rather than by headline price. The definitions are set out in how pricing works, and the method for comparing is in our buyer's guide.

How the market has changed

2024 to early 2025: growth and shortage. Demand outran manufacturing. The 12.5mg and 15mg pens ran short from March 2025, recovering through the spring. Prices were comparatively low and pharmacies competed hard on discounts to win long-term patients. Our supply guide records that period.

September 2025: the price rise. Eli Lilly increased UK list prices sharply, with the highest doses roughly doubling. Pharmacies absorbed part of it, but monthly costs rose across the board. Demand fell, some patients stepped down a dose or stopped, and the market shifted from competing on discounts to competing on retention.

2026: retention and plans. Supply is normal at every strength. The visible competition is now in multi-month plans, bundles and price-match promises, all of which are designed to stop you shopping around each month. Some cost less per pen. Others are harder to leave. Our guides to bundles and price matching cover both.

What to watch next

• NHS expansion. Each phase of the roll-out moves some patients from the private market to the NHS and changes private demand.
• Competing medicines. Oral GLP-1s and new injectables reaching the UK would give the market its first real substitute and put downward pressure on price.
• Consolidation. Smaller pharmacies being bought by larger groups tends to remove the cheapest listings from the market.
• Regulatory attention. Advertising rules for prescription-only medicines and the GPhC's distance-selling standards both shape how aggressively pharmacies can market.